Immunovant Inc expected to post a loss of 53 cents a share - Earnings Preview

Immunovant

06/08/2024 14:55

* Immunovant Inc  IMVT.OQ   IMVT.O  is expected to show no
change
in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Immunovant Inc is for a
loss
of 53 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunovant
Inc is
$49.00​, above​ its last closing price of $26.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.41       -0.43      -0.52     Missed  -21.9
 Dec. 31 2024  -0.44       -0.43      -0.36     Beat    16.5
 Sep. 30 2023  -0.50       -0.47      -0.45     Beat    4.4​
 Jun. 30 2023  -0.47       -0.45      -0.57     Missed  -27.7
 ​​Jan.        -0.45       -0.43      -0.46     Missed  -7.5
 1 0001                                                 
 Dec. 31 2022  -0.40       -0.39      -0.49     Missed  -26.1​
 Sep. 30 2022  -0.39       -0.39      -0.41     Missed  -4.8
 Jun. 30 2022  -0.39       -0.40      -0.35     Beat    11.6
 This summary was machine generated August 6 at 13:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)